Evidence map›Paper›PMID 38307876›Full record

ArticleScientific reports2024

Knockdown of Hyaluronan synthase 2 suppresses liver fibrosis in mice via induction of transcriptomic changes similar to 4MU treatment.

Noreen Halimani, Mikhail Nesterchuk, Alexandra A Tsitrina, Marat Sabirov, Irina N Andreichenko, Nataliya O Dashenkova, Elizaveta Petrova, Alexey M Kulikov, Timofei S Zatsepin, Roman A Romanov and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Noreen HalimaniVladimir Zelman Center for Neurobiology and Brain Rehabilitation and Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, 143025, Russia. noreen.halimani@skoltech.ru.
Mikhail NesterchukVladimir Zelman Center for Neurobiology and Brain Rehabilitation and Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, 143025, Russia.
Alexandra A TsitrinaIKI-Ilse Katz Institute for Nanoscale Science & Technology, Nem Gurion University of the Negev, Beersheba, Israel.
Marat SabirovKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow, 119334, Russia.
Irina N AndreichenkoAO Reproduction Head Centre of Agricultural Animals, Tsentralnaya Street, 3., Podolsk, Moscow Region, 142143, Russia.
Nataliya O DashenkovaKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow, 119334, Russia.
Elizaveta PetrovaVladimir Zelman Center for Neurobiology and Brain Rehabilitation and Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, 143025, Russia.
Alexey M KulikovKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow, 119334, Russia.
Timofei S ZatsepinDepartment of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia.
Roman A RomanovDepartment of Molecular Neurosciences, Center for Brain Research, Medical University of Vienna, Vienna, Austria.
Arsen S Mikaelyan *Koltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow, 119334, Russia.
Yuri V Kotelevtsev *Vladimir Zelman Center for Neurobiology and Brain Rehabilitation and Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, 143025, Russia.
Koltzov Institute of Developmental Biology · RUSkolkovo Institute of Science and Technology · RUBen-Gurion University of the Negev · ILInstitute for Animal Reproduction · JPLomonosov Moscow State University · RUMedical University of Vienna · AT

Funding

IDB RAS 0088-2021-0017Ministry of Science and Higher Education of the Russian Federation 075-15-2021-1075Russian Foundation for Basic Research 19-29-04123
6 · The paper itself

Abstract

Hepatic fibrosis remains a significant clinical challenge due to ineffective treatments. 4-methylumbelliferone (4MU), a hyaluronic acid (HA) synthesis inhibitor, has proven safe in phase one clinical trials. In this study, we aimed to ameliorate liver fibrosis by inhibiting HA synthesis. We compared two groups of mice with CCl

Indexed as

Hyaluronic AcidHymecromoneAnimalsGene Expression ProfilingHyaluronan SynthasesLiver CirrhosisMiceRNA, Small InterferingHas2 protein, mouseHyaluronan SynthasesHyaluronic AcidHymecromoneRNA, Small Interfering

Identifiers

PMID38307876
PMCPMC10837461
OpenAlexW4391486079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.